Osmotica Pharmaceuticals (NASDAQ:OSMT) is set to release its earnings data after the market closes on Wednesday, March 27th.

Shares of OSMT stock opened at $6.49 on Monday. The company has a quick ratio of 1.07, a current ratio of 1.29 and a debt-to-equity ratio of 0.75. Osmotica Pharmaceuticals has a 52 week low of $6.03 and a 52 week high of $9.90.

A hedge fund recently bought a new stake in Osmotica Pharmaceuticals stock. Geode Capital Management LLC bought a new stake in Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 86,316 shares of the company’s stock, valued at approximately $668,000. Geode Capital Management LLC owned 0.17% of Osmotica Pharmaceuticals as of its most recent SEC filing. 12.76% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Osmotica Pharmaceuticals (OSMT) Set to Announce Earnings on Wednesday” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/osmotica-pharmaceuticals-osmt-set-to-announce-earnings-on-wednesday/2915480.html.

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods.

See Also: What is the LIBOR?

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.